Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients

• Status: RECRUITING
• Trial end date: 2026-12-20

Summary

Gout is a systemic disease that results from the deposition of monosodium urate crystals (MSU) in tissues. Increased serum uric acid (SUA) above a specific threshold (\>6.8 mg/dl) is a requirement for the formation of uric acid crystals. MSU crystals can be deposited in all tissues mainly in and around the joints forming tophi. Early presentation of gout is an acute joint inflammation that is quickly relieved by non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine. Lowering SUA levels below deposition threshold either by dietary modification or using serum uric acid lowering drugs is the main goal in management of gout. This results in dissolution of MSU crystals preventing further attacks

• Phase: PHASE2

Details

• Lead Sponsor: Mostafa Bahaa
• Collaborators: Dalia Naser Abdel-Sadek Safa , Faculty of Pharmacy, Tanta University; Sahar Mohamed Elhaggar, Faculty of Pharmacy, Tanta University; Tarek Mohamed Abd-Elazez Nasr-Allah, Faculty of Medicine - Al-Azhar University
• Treatments: Febuxostat; Metformin